NJ's Psilocybin Therapy Bill Clears Another Senate Committee As Legalization Gains Momentum

Zinger Key Points
  • New Jersey’s Psilocybin Behavioral Health Access and Services Act advanced from the Senate Budget Committee to the Senate's Second Reading.
  • If passed, the legislation would establish a legal framework for psilocybin cultivation, manufacturing, testing, and administration.

New Jersey is making significant strides toward legalizing psychedelic-assisted therapy, as the state's Psilocybin Behavioral Health Access and Services Act advanced through the Senate Budget Committee on Monday. As reMind reported, this move marks another crucial step for the bill, which had already been approved by the Senate Health Committee.

The bill now heads to the second reading in the Senate, where a full vote will be the next hurdle if support continues. The Assembly Health Committee is still reviewing the bill.

If passed, the legislation would establish a legal framework for psilocybin cultivation, manufacturing, testing and administration. This system would create a therapeutic model for adult use under professional supervision to treat various mental health conditions.

"Scientific research is showing that psilocybin can be a safe and effective treatment for severe depression, anxiety, and other mental health disorders," said senate president Nick Scutari, who co-sponsored the bill with Senator Joe Vitale. "This bill will create a framework for a program that offers professionally supervised services to qualified patients who would benefit from psilocybin treatment. This has the potential to make a real difference in the lives of those who suffer from adverse behavioral health conditions," Scutari added.

Licensing And Regulations

If enacted, the bill would give the New Jersey Department of Health oversight of psilocybin-related operations, including manufacturing, service centers, facilitators and testing labs. Psilocybin use would be limited to licensed service centers, where patients can prepare for and safely experience the substance with optional integration sessions.

The bill’s momentum was further reinforced by a favorable vote from the Senate Budget Committee with 12 ayes and one abstention. Lisa Gora, partner at Epstein, Becker & Green P.C. noted that even previously hesitant lawmakers seemed convinced by recent amendments and compelling testimony from advocates. “Advancement and momentum for this bill continues!” Gora said.

Public Opinion And Legislative Challenges

New Jersey's push for psilocybin legalization follows failed attempts in states like California and Connecticut, where legislative complexities derailed similar efforts. However, public opinion in New Jersey appears to be with the the bill. According to a poll by Stockton University's William J. Hughes Center for Public Policy, 55% of respondents supported legalizing psilocybin for medical use, while only 20% opposed it.

Cover image made with AI

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Cannabis is evolving – don’t get left behind!

Curious about what’s next for the industry and how to leverage California’s unique market?

Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!

Get your tickets now to secure your spot and avoid last-minute price hikes.